跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Approved
STANDARD
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Sandoz Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
468abc753636999f
Company
Sandoz Pty Ltd
Type
Standard
Approval Details
Approval Id
468abc753636999f
Product Name
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Artg Id
425612
Artg Name
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Sponsor
Sandoz Pty Ltd
Company Detail Path
/organization/sandoz-pty-ltd
Artg Date
2025-04-04
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
468abc753636999f
Type
Standard
Back to TGA Approvals
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial - TGA Drug Approval Details
